Literature DB >> 20059453

The prefrontal cortex: a target for antipsychotic drugs.

F Artigas1.   

Abstract

OBJECTIVE: At therapeutic doses, classical antipsychotic drugs occupy a large proportion of subcortical dopamine D2 receptors, whereas atypical antipsychotics preferentially occupy cortical 5-HT(2) receptors. However, the exact cellular and network basis of their therapeutic action is not fully understood.
METHOD: To review the mechanism of action of antipsychotic drugs with a particular emphasis on their action in the prefrontal cortex (PFC).
RESULTS: The PFC controls a large number of higher brain functions altered in schizophrenia. Histological studies indicate the presence of a large proportion of PFC neurons expressing monoaminergic receptors sensitive to the action of atypical- and to a lesser extentclassical antipsychotic drugs. Functional studies also indicate that both drug families act at PFC level.
CONCLUSION: Atypical antipsychotic drugs likely exert their therapeutic activity by a preferential action on PFC neurons, thus modulating the PFC output to basal ganglia circuits. Classical antipsychotics also interact with these PFC targets in addition to blocking massively striatal D2 receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20059453     DOI: 10.1111/j.1600-0447.2009.01455.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  21 in total

Review 1.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

2.  Analysis of 5-HT(2A) receptor binding with [(11)C]MDL 100907 in rats: optimization of kinetic modeling.

Authors:  Anniek K D Visser; Erik F J De Vries; Nisha K Ramakrishnan; Antoon T M Willemsen; Fokko J Bosker; Johan A den Boer; Rudi A J O Dierckx; Aren van Waarde
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

3.  Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs.

Authors:  Jesse Wood; Yunbok Kim; Bita Moghaddam
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

4.  Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and σ(1) receptor activation.

Authors:  Yukio Ago; Koji Yano; Naoki Hiramatsu; Kazuhiro Takuma; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

Review 5.  Catecholamine/Serotonin interactions: systems thinking for brain function and disease.

Authors:  Julie G Hensler; Francesc Artigas; Analía Bortolozzi; Lynette C Daws; Philippe De Deurwaerdère; Léa Milan; Sylvia Navailles; Wouter Koek
Journal:  Adv Pharmacol       Date:  2013

6.  Acetylcholine α7 nicotinic and dopamine D2 receptors are targeted to many of the same postsynaptic dendrites and astrocytes in the rodent prefrontal cortex.

Authors:  Aine M Duffy; Megan L Fitzgerald; June Chan; Danielle C Robinson; Teresa A Milner; Kenneth Mackie; Virginia M Pickel
Journal:  Synapse       Date:  2011-12       Impact factor: 2.562

7.  Prefrontal deviations in function but not volume are putative endophenotypes for schizophrenia.

Authors:  Sheena F Owens; Marco M Picchioni; Ulrich Ettinger; Colm McDonald; Muriel Walshe; Anne Schmechtig; Robin M Murray; Fruhling Rijsdijk; Timothea Toulopoulou
Journal:  Brain       Date:  2012-06-12       Impact factor: 13.501

8.  Neural Substrates of Dopamine D2 Receptor Modulated Executive Functions in the Monkey Prefrontal Cortex.

Authors:  M Victoria Puig; Earl K Miller
Journal:  Cereb Cortex       Date:  2014-05-09       Impact factor: 5.357

9.  Cognitive Brain Signatures of Youth With Early Onset and Relatives With Schizophrenia: Evidence From fMRI Meta-analyses.

Authors:  Marie Arsalidou; Zachary Yaple; Tomas Jurcik; Vadim Ushakov
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

Review 10.  Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

Authors:  Pau Celada; Analía Bortolozzi; Francesc Artigas
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.